INTRODUCTION
Mast cells have been implicated in the generation of an angiogenic response in various in vitro and in vivo studies (Kessler et al., 1976; Azizkhan et al., 1980; Wilson, 1985; Clinton et al., 1988; Starkey et al., 1988; Norrby et al., 1989; Meininger et al., 1995) . The intimate anatomic association between mast cells and the vasculature and the increased rate of appearance of the cells during tumor growth, wound healing, and inflammation, processes that are all accompanied by neovascularization, support this assumption (Meininger and Zetter, 1992) . The mechanism of mast cellmediated angiogenesis has been mainly ascribed to the effects of released heparin and histamine (Azizkhan et al., 1980; Marks et al., 1986) . Heparin, however, seems not to mediate a direct angiogenic effect, but it potentiates the mitogenic effects of heparin-binding growth factors, such as basic fibroblast growth factor (bFGF) 1 and vascular endothelial growth factor (VEGF) (Gitay-Goren et al., 1992) . Recently, the expression of various cytokines was identified in human mast cells (Okayama et al., 1995) . These include tumor necrosis factor-␣ (TNF-␣) and interleukin (IL)-8, which were both identified as angiogenic growth factor in vivo and in vitro (Leibovich et al., 1987; Strieter et al., 1995) . While IL-8 is produced only after appropriate stimulation in mast cells (Mö ller et al., 1993) , TNF-␣ is stored already preformed and therefore available for immediate release (Walsh et al., 1991) .
bFGF, another potent angiogenic growth factor, has also been recently identified in human mast cells (Reed et al., 1995; Qu et al., 1995) , but it lacks the typical signal peptide region necessary for its secretion. Mast cell-associated granules are a rich source of heparin and, consequently, it may be suspected that they serve as depots that are released during degranulation (Reed et al., 1995; Qu et al., 1995) .
In the present report, we provide evidence that mast cells express VEGF and discuss their role in VEGFdependent angiogenic processes. VEGF, also known as vascular permeability factor (VPF), is characterized by its highly specific mitogenic activity for endothelial cells and its angiogenic effect observed in vitro and in vivo (Ferrara et al., 1992) . The VEGF family consists of at least four isoforms arising from alternative mRNA splicing (Tischer et al., 1991) . VEGF 121 and VEGF 165 were found to be secreted by a wide spectrum of cell types, including smooth muscle cells , fibroblasts and epithelial cells (Pertovaara et al., 1994) , keratinocytes , macrophages , cardiac myocytes (Ladoux and Frelin, 1993) , and various tumor cells (Ferrara et al., 1992) . The two larger isoforms, VEGF 189 and VEGF 206 , share a strong heparin-binding site and, consequently, they predominantly occur as cell-associated isoforms. The specific biological significance of VEGF 189 and VEGF 206 is unclear since only a few indications for their precise tissue expression exist (Houck et al., 1991; Bacic et al., 1995) . Using cells derived from a patient with mast cell leukemia (HMC-1 cells, Butterfield et al., 1988) and mast cells isolated from human foreskin, we investigated the expression of VEGF isoforms on the level of RNA by Reverse transcription-polymerase chain reaction (RT-PCR) and on the level of protein by Western blotting, flow cytometry, enzyme-linked immunosorbent assay (ELISA), and immunoelectron microscopy. In addition to the identification of VEGF in mast cells, these methods allowed the discrimination between VEGF stored intracellularly and VEGF released after appropriate cell stimulation.
MATERIALS AND METHODS

Cell Culture
HMC-1 cells (kindly provided by Dr. Butterfield, Rochester, MN), which are immature human leukemic mast cells (Butterfield et al., 1988; Hamann et al., 1994) , were cultured in Iscove's medium (Seromed, Berlin, Germany), supplemented with 10% fetal calf serum (FCS) (Seromed), 10 M monothiolglycerol (Sigma Chemical, Deisenhofen, Germany), and antibiotics (streptomycin and penicillin). Stimulation of HMC-1 cells was performed in 24-multiwell plates (Falcon, Lincoln Park, NJ), as previously described (Mö ller et al., 1993) . Before stimulation, cells were cultured for 24 h in medium without FCS. After this time, 2 ϫ 10 6 cells were incubated for the times indicated in medium without FCS containing 25 ng/ml PMA (Sigma) and 250 nM calcium ionophore A23187 (Sigma). Stimulation periods longer than 12 h induced a decrease in cell viability to 85-90% as determined by trypan blue exclusion. To inhibit protein synthesis, in some experiments cycloheximide (CHX, Sigma) at a concentration of 1 M was added during stimulation.
For human microvascular endothelial cell (HMVEC) proliferation studies, the conditioned medium (CM) of unstimulated cells was used alone. For this purpose, HMC-1 cells were cultured for 24 h under the same conditions as described above for cell stimulation, but in the absence of PMA and A23187. CM was concentrated 10-fold by ultrafiltration in Centriprep-10 filter units (Amicon, Beverly, MA), and supernatants were stored frozen at Ϫ80°C for up to 2 wk.
HMVEC were obtained from Clonetics Cell Systems (Remagen, Germany). These cells were routinely grown in endothelial cell basal medium (EBM, Clonetics), supplemented with 5% FCS, 10 ng/ml recombinant human epidermal growth factor, 1.0 g/ml hydrocortisone, 50 g/ml gentamicin, 50 ng/ml amphotericin-B, and 12 g/ml bovine brain extract. All supplements were provided by Clonetics. Cells were passaged by trypsinization when they reached 80 -90% confluency.
HMVEC Proliferation Assay
Second-to fifth-passage HMVEC were seeded at 5 ϫ 10 3 cells/cm 2 in 24-multiwell plates (Falcon) as triplicates in EBM, supplemented as described above. After 8 h, medium was changed and adherent cells were cultured for 4 d in EBM medium without hydrocortisone and bovine brain extract, but containing various amounts of VEGF 165 (RD Systems, Wiesbaden-Nordenstadt, Germany), or concentrated conditioned HMC-1 medium. To demonstrate VEGF-specific effects, a neutralizing monoclonal antibody (mAb, clone 26503.11, RD Systems) was used in the proliferation assay at a concentration of 1 g/ml. As a control, an inappropriate isotype antibody (mouse immunoglobulin [Ig]G 2b , Dianova, Hamburg, Germany) was used at the same concentration. Cells were harvested by trypsinization (0.025% trypsin/0.01% EDTA, Clonetics), fixed with 1% paraformaldehyde, and counted with a cell counter/analyzer (CASY 1/TT, Schärfe System, Reutlingen, Germany).
Enrichment of Human Skin Mast Cells by Counterflow Centrifugal Elutriation (CCE)
The epidermis of human foreskin was enzymatically detached by an overnight incubation at 4°C with dispase (Boehringer, Mannheim, Germany) at a concentration of 1 mg/ml. The remaining dermis was dispersed by an incubation with collagenase I (Worthington Biochemical, Freehold, NJ) for 2 h at 37°C. Elutriation was performed at 10°C and constant rotor speed (2300 Ϯ 10 rpm) using a Beckmann JE5-elutriator rotor equipped with a Sanderson chamber (Beckmann Instruments, Palo Alto, CA). Phosphate-buffered saline (PBS) con- 
RT-PCR Amplification and Sequence Analysis
Semiquantitative RT-PCR analysis was performed as previously described (Krü ger-Krasagakes et al., 1994) . Briefly, 3 g of total cellular RNA, extracted from HMC-1 cells by applying an RNeasy total RNA kit (Quiagen, Hilden, Germany), was transcribed into cDNA using random priming. For comparison of VEGF mRNA levels in different samples, cDNAs were first adjusted to equal concentrations of ␤-actin by the use of a ␤-actin control fragment (Krü ger- Krasagakes et al., 1994) and then analyzed for their content of VEGF mRNA. Primer sequences for ␤-actin (bases 103-122 and 642-619) were taken from Yamamura et al. (1991) , and those for VEGF were obtained from Weindel et al. (1992) and from Morii et al. (1993) , respectively. Cycles were 5 min at 94°C, 45 s at 94°C, 60 s at 60°C, 1 min at 72°C, and 5 min at 72°C in a temperature cycler (Hybaid, Middlesex, England). Thirty-five cycles were performed. For the amplification of a VEGF 206 -specific cDNA fragment, sense and antisense primers were designed as shown in Figure 2A , and the same conditions as described above were applied. The corresponding band was cut from the gel, eluted, and automatically sequenced by an ABI sequencer (model 377; Applied Biosystems, Weiterstadt, Germany).
Western Blot Analysis of CM
The CM of unstimulated cells and HMC-1 cells stimulated for 24 h with PMA and calcium ionophore A23187 was concentrated by ultrafiltration in Centriprep-10 filter units (Amicon) and incubated overnight at 4°C with precleaned heparin-acrylic beads (Sigma). The heparin beads were collected by centrifugation, washed two times, and boiled for 10 min in sample buffer containing 2.5% 2-mercaptoethanol. Equal amounts of protein were electrophoresed under reducing and nonreducing conditions on a 12% SDS polyacrylamide gel. Separated proteins were blotted to nitrocellulose membranes (Schleicher & Schü ll, Dassel, Germany). The membranes were blocked with PBS containing 0.1% Tween 20 and 5% skimmed milk powder for 1 h at room temperature. The primary rabbit antihuman VEGF polyclonal antibody (Pepro Tech, Rocky Hill, NY) and a rabbit control IgG (Dianova, Hamburg, Germany) were diluted at a concentration of 2 g/ml and incubated with the membranes overnight at 4°C. After intense washing, the membranes were incubated with the secondary horseradish peroxidase-conjugated goat anti-rabbit IgG (Dako, Hamburg, Germany) at a concentration of 0.125 g/ml for 2 h at room temperature. Thereafter, the membranes were washed once again and incubated in enhanced chemiluminescence (ECL, Amersham, Little Chalfont, England) substrate reagent for 1 min. The blot was exposed to film (ECL Hyperfilm, Amersham) for 30 -90 s, and the molecular weights of the immunodetected bands were compared with low molecular weight standards (Sigma).
ELISA
The time-dependent secretion of VEGF and bFGF under nonstimulating and stimulating conditions was measured with growth factorspecific ELISA kits (Quantikine, RD Systems), according to the instructions of the manufacturer. The lower detection limit for VEGF was 15 pg/ml and 5 pg/ml for bFGF. Concentrations of VEGF in the samples were calculated by interpolation from the standard curve.
Flow Cytometric Quantification of Intracellular VEGF
VEGF stored intracellularly in HMC-1 cells was monitored after cell fixation, partial cell permeabilization, and staining with a VEGFspecific mAb (clone 26503.11, RD Systems) (Grü tzkau et al., 1997) . Briefly, 5 ϫ 10 5 cells were fixed at 4°C for 10 min in a mixture of 4% paraformaldehyde and 0.1% glutaraldehyde. After intense washing, cells were permeabilized with 50 l PBS containing 5% BSA (Sigma) and 0.03% Saponin (Sigma) and were incubated for 30 min on ice. Thereafter, the VEGF-specific mAb was added at a concentration of 50 g/ml, and cells were once again incubated for 30 min on ice. After washing, a secondary dichlorotriazinylamino-fluorescein-conjugated F(abЈ) 2 fragment of goat anti-mouse IgG antibodies (Dianova) was added at a concentration of 20 g/ml, and cells were incubated for an additional 30 min at 4°C. Finally, cells were washed and fixed in PBS containing freshly prepared 1% paraformaldehyde. At least 10,000 cells were analyzed using an EPICS XL flow cytometer (Coulter Electronics, Krefeld, Germany). Results were expressed as percent positive cells, taking into account the amount of unspecific binding of the corresponding isotype control antibody.
Postembedding Immunoelectron Microscopy
The identification and ultrastructural localization of VEGF in human skin mast cells, enriched by CCE as described above, were performed by postembedding immunoelectron microscopy. The mast cell-enriched cell preparation was fixed in 4% paraformaldehyde for 10 min at room temperature, after which cells were centrifuged in molten agar (1% in 0.1 M PBS at 45°C) to form cell pellets that were sliced and processed as small blocks. Dehydration performed in a graded series of ethanol solutions at 4°C was followed by an infiltration with LR-White resin (London Resin, Berkshire, England) without accelerator (Newman and Hobot, 1987) . Polymerization was induced by the addition of the manufacturer's accelerator for 2 h at 4°C. Ultrathin sections (70 nm) were picked up on formvar-coated nickel grids.
Immunostaining was performed on 50 l-droplets in a moist chamber using a VEGF-specific mAb (clone 26503.11, RD Systems) at a concentration of 30 g/ml and a secondary colloidal gold (10 nm)-labeled goat anti-mouse IgG (AuroProbe, Amersham) at a 1:20 dilution. Poststaining was performed with 5% aqueous uranyl acetate (Merck, Darmstadt, Germany) for 15 min. Staining specificity was checked by substituting the primary antibody with an inappropriate isotype antibody. Specimens were examined with a Zeiss EM906 transmission electron microscope (Carl Zeiss, Thornwood, NY) at 80 kV.
RESULTS
Detection of VEGF mRNA from HMC-1 Cells by Semiquantitative RT-PCR
Amplification of cDNA from unstimulated HMC-1 cells and cells stimulated for 24 h with PMA/A23187 with two different pairs of primers gave rise to up to four bands of 510 base pairs (bp), 650 bp, 720 bp, and 770 bp ( Figure 1A ) and 400 bp, 540 bp, 610 bp, and 660 bp, respectively (our unpublished results)-the sizes predicted for VEGF 121 , VEGF 165 , VEGF 189 , and VEGF 206 (Weindel et al., 1992; Morii et al., 1993) . While the three smaller VEGF isoforms were already expressed in unstimulated cells, the largest, strongly heparin-binding isoform was only detectable in cells stimulated for at least 24 h in the presence of 25 ng/ml PMA and 250 nM calcium ionophore A23187. Since equal amounts of cDNAs of unstimulated and stimulated cells were used for RT-PCR, it was feasible to compare the intensities of products amplified. The total amount of VEGF mRNA expressed in unstimulated cells was obviously lower in comparison to stimulated cells. RT-PCR performed with higher amounts of cDNA of unstimulated cells did not result in the appearance of the VEGF 206 -specific amplicon, indicating that the expression of the VEGF 206 -transcript is stimulus dependent in HMC-1 cells (our unpublished results).
For the unambiguous identification of VEGF 206 , we used a VEGF 206 -specific pair of primers ( Figure 2A ) and identified the resulting amplicon by sequence analysis. In accordance with the results described in Figure 1A , we could detect a single PCR product of 438 bp, the size predicted for VEGF 206 , only in stimulated HMC-1 cells ( Figure 1B ). Sequence analysis revealed that the amplified product contained the VEGF 206 -specific nucleotide sequence with complete homology ( Figure 2B ).
Detection of VEGF Isoforms in the CM of HMC-1 Cultures by Western Blot Analysis
To clarify whether VEGF isoforms are expressed at the protein level and which isoforms are released after appropriate stimulation, Western blot analysis was performed with a rabbit anti-human VEGF polyclonal antibody. For this purpose, concentrated supernatants of HMC-1 cells cultured for 24 h in the presence of PMA and the calcium ionophore A23187, together with an unstimulated control, were preadsorbed with heparin coupled to acrylic beads to enrich heparinbinding VEGF isoforms. Precleaning of supernatants with heparin beads was necessary to minimize background staining, but during this step, VEGF 121 was lost to a large extent. Under nonreducing conditions, a broad band between 45 kDa and 60 kDa was visible in all supernatants investigated (Figure 3, lane 3) . In the ) and HMC-1 cells stimulated for 24 h with PMA/A23187 (lanes 2, 3, and 6) were used for SDS-PAGE analysis and blotting on nitrocellulose membranes. Precleaning of supernatants with heparin beads was necessary to minimize background staining, but during this step, VEGF 121 was lost to a large extent. Recombinant human VEGF 165 was used as positive control (lanes 4 and 5). Lanes 1-5 were probed with an VEGF-specific antibody, and lane 6 was probed with an isotype-specific control antibody.
presence of 2-mercaptoethanol, three bands (18 kDa, 22 kDa, and 27 kDa) were detectable in the supernatant of unstimulated and stimulated cells (Figure 3 , lanes 1 and 2), which correspond to the predicted molecular size for VEGF 121 (17 kDa), VEGF 165 (23 kDa), and VEGF 189 (26 kDa) in reducing conditions. Since identical cell numbers were used to prepare the CM from unstimulated and stimulated cells, it is possible to compare the amounts of the various isoforms released. In accordance with the data obtained by the VEGF-specific ELISA, stimulated cells released significantly higher amounts of VEGF 121 , VEGF 165 , and VEGF 189 . In the supernatant of stimulated cells, an additional protein of 30 kDa, most probably representing VEGF 209 , was detectable ( Figure 3, lane 2) .
These results demonstrate that HMC-1 cells possess the capability of synthesizing and secreting all known VEGF isoforms.
Time-and Stimulus-dependent Secretion of VEGF Determined by an ELISA
The time course of VEGF synthesis and secretion was monitored in unstimulated HMC-1 cells and in cells costimulated with PMA and calcium ionophore A23187. HMC-1 cells cultured for 24 h in the absence of any stimulus released VEGF continuously into the surrounding medium (Figure 4) . Stimulation of cells caused a significant increase in VEGF secretion that was already detectable after 3 h. The continuously stimulated as well as the unstimulated release of VEGF was completely stopped in the presence of CHX (Figure 4) .
In parallel, we determined the release of bFGF in the supernatants of stimulated and unstimulated cells but detected only minimal amounts (5 pg/ml) in cells stimulated for 48 h with PMA and A23187 (our unpublished results).
Determination of Cell-associated VEGF by Flow Cytometry
Flow cytometry was used to determine whether HMC-1 cells not only synthesize and release VEGF but are also capable of storing this factor intracellularly. After appropriate cell fixation and permeabilization, labeling with an anti-VEGF mAb resulted in 75% Ϯ 20% positively stained cells ( Figure 5 ). The efficiency of permeabilization was routinely checked by staining for CD68, an intracellularly located antigen expressed by nearly 100% of HMC-1 cells. Stimulation of HMC-1 cells showed no significant effect on the amount of cell-associated VEGF (our unpublished data). The intracellular amount of VEGF remained also unchanged after cells had been treated with 1 M CHX (our unpublished data).
To detect VEGF possibly expressed on the plasma membrane, we analyzed unpermeabilized cells that were not fixed before staining. Under these conditions, however, no VEGF was detectable on the surface of unstimulated cells and cells stimulated with PMA and A23187 (our unpublished data). 
Identification of Bioactive VEGF in the CM of HMC-1 Cells
The CM of unstimulated HMC-1 cells was tested for its mitogenic activity in an HMVEC proliferation assay. Addition of various amounts of CM induced a dose-dependent increase in HMVEC proliferation rate and at 100% CM (i.e., 0.1 volume of 10-fold concentrated HMC-1 supernatant was added to the proliferation assay), an effect comparable to 10 ng/ml VEGF 165 was observed (Figures 6 and 7A ). This effect was suppressed up to 90% in the presence of a neutralizing VEGF-specific mAb or up to 75% by a preincubation of the CM with heparin-conjugated agarose beads ( Figure 7A ). The antibody used showed its halfmaximal inhibitory effect at a concentration of 25 ng/ml ( Figure 7B) . A control antibody showed no inhibitory effect ( Figure 7A ).
Identification and Ultrastructural Localization of VEGF in Human Skin Mast Cells
Under physiological conditions, mast cells are only found scarcely scattered in the tissue, a circumstance that makes it difficult to analyze a sufficient amount of mast cells during immunoelectron microscopic evaluation of VEGF expression. Therefore, we decided to enrich human skin mast cells by counterflow elutriation, which allows the identification of VEGF expression, and the ultrastructural localization of the molecule in a significant number of mast cells by postembedding immunoelectron microscopy. By this method, we could enrich mast cells up to 30%, as estimated after flow cytometric analysis of the cellspecific surface receptor for c-kit and IgE (our unpublished data). In addition to mast cells, macrophages, endothelial cells, and fibroblasts were also present in this cell population. For electron microscopic evaluation, mast cells were unambiguously identifiable by their characteristic ultrastructure, namely a monolobed nucleus with partially condensed peripheral chromatin and numerous granules filled with electron-dense material ( Figure 8A ). As can be seen, the isolation method caused almost no piecemeal or anaphylactic degranulation of cells. As shown in Figure  8B , positive staining for VEGF was detected exclusively in mast cell-specific granules. Immunolabeling varied, however, among granules on a quantitative basis, and some granules exhibited no immunogold labeling at all. The cytoplasm in the vicinity of the granules, the plasma membrane, and the nucleus showed no significant immunostaining. In other dermal cells present in the cell suspension, no VEGF was detectable at all. Background labeling was minimal, and no immunoreactive structures were seen in mast cells processed in the presence of an isotype-matched irrelevant mAb ( Figure 8C ).
DISCUSSION
In this report, we present for the first time evidence indicating that human mast cells express all known isoforms of VEGF. Additionally, we were able to shed Figure 6 . Proliferation of HMVEC in response to HMC-1 cellderived supernatants. The CM of unstimulated HMC-1 cells was concentrated 10-fold by ultrafiltration, and dilutions were tested for its mitogenic activity in an HMVEC proliferation assay. A dosedependent increase in HMVEC proliferation rate was detectable. Results are shown for one representative experiment performed in triplicate. Similar results were obtained in four independent experiments (our unpublished data). light on the hitherto unknown physiological role of the strongly heparin-binding isoforms VEGF 189 and VEGF 206 . To our knowledge, the expression of VEGF in mast cells has only been investigated up to now at the level of mRNA in HMC-1 cells (Ito et al., 1995) . In this report, however, no VEGF mRNA was detectable in unstimulated cells by Northern blot analysis. Semiquantitative RT-PCR experiments performed in the present study allowed us to determine a relative abundance of VEGF 121 , VEGF 165 , VEGF 189 , and VEGF 206 mRNA in HMC-1 cells. While the mRNA for the three major VEGF forms (121, 165, and 189 amino acids) was apparent already in unstimulated cells, the largest, strongly heparin-binding isoform was only detectable in HMC-1 cells stimulated with a combination of the calcium ionophore A23187 and PMA for at least 24 h. The obvious discrepancy between our results and the results of Ito et al. (1995) is possibly based on the different sensitivity of the detection methods applied.
Similar to bovine smooth muscle cells , human keratinocytes , glioma cells , and retinal epithelial cells (Shima et al., 1995) , HMC-1 cells already constitutively expressed measurable amounts of VEGF in vitro, as could be shown not only at the level of mRNA (PCR), but also at the protein level by ELISA and Western blotting. The rate of secretion was increased 2.5-fold in response to the combination of PMA and the calcium ionophore A23187. Therefore, it is reasonable to predict that mast cells may enhance synthesis of VEGF in vivo when activated under inflammatory conditions. Since HMC-1 cells only variably express the highaffinity receptor for IgE (Hamann et al., 1994; Nilsson et al., 1994) , an IgE-like activation of these cells was achieved by triggering calcium influx, combined with PKC activation (Sagi-Eisenberg, 1993) . HMC-1 cells activated in this way start de novo synthesis of various mediators, such as IL-1␤, IL-6, IL-8, and bFGF (Grabbe et al., 1995; Qu et al., 1995) . VEGF expression is inducible in many different cell types by a direct pharmacological activation of PKC, which phosphorylates AP-1, the transcription factor thought to be mainly responsible for the regulation of VEGF expression (Kolch et al., 1995) . For IL-1␤, also known to activate AP-1, a stimulating effect on VEGF gene transcription in rat aortic smooth muscle cells has been ascertained as well (Li et al., 1995) .
The high contents of heparin found in the secretory granules of mast cells (Stevens et al., 1988) made it reasonable to assume that these cells are a major source for the strongly heparin-binding isoforms VEGF 189 and VEGF 206 . This assumption was confirmed by our findings that in human skin mast cells, VEGF was exclusively detectable within the specific mast cell granules. The observation that in stimulated HMC-1 cells, an increase in VEGF release (ELISA data) was not accompanied by a decrease in intracellular VEGF-contents (FACS data) also indicates that a distinct cell-associated VEGF-pool exists in HMC-1 cells that is not completely releasable. This pool probably represents VEGF bound to heparin proteoglycans. No VEGF immunoreactivity was found on the plasma membrane of skin mast cells (immuno EM data) and of HMC-1 cells (FACS data), although heparin proteoglycans are present also as integral membrane proteins of almost all cell surfaces (Yanagishita and Hascall, 1992) . VEGF bound to extracellular matrix components is releasable in its soluble form by heparin or enzymatically by plasmin without restriction of its mitogenic activity (Park et al., 1993) .
So far, few reports exist about the physiological significance and the way in which these strongly cellbinding isoforms are released (Park et al., 1993; Bacic et al., 1995) . While VEGF 189 is distributed in the majority of cells and tissues expressing the VEGF gene, VEGF 206 represents a very rare isoform that has only been detected in a human fetal liver cDNA library so far (Houck et al., 1991 (Minchenko et al., 1994) .
The role of VEGF 189 and VEGF 206 as paracrine mediator of angiogenesis in vivo has been disputed because so far, no secretory mechanism is known for these isoforms. Identification of mast cells as a source for the complete spectrum of VEGF isoforms provides secretion via degranulation or by direct cell-cell transfer (transgranulation) as a plausible mechanism by which this cytokine is released into the tissue or into other cells. Evidence for at least the first possibility is provided by the finding that in the supernatant of PMA/A23187-stimulated HMC-1 cells, the strongly heparin-binding isoforms were detectable by Western blotting. Similar assumptions were made for the release of bFGF, which lacks a signal sequence necessary for its secretion (Qu et al., 1995; Reed et al., 1995) . In the supernatant of stimulated HMC-1 cells, where bFGF was identified on the mRNA and protein level (Qu et al., 1995) , we could however detect only minor amounts of bFGF (Յ 5 pg/ml), which are insufficient to provoke a mitogenic response in endothelial cells or to synergize with VEGF for its mitogenic activity (Goto et al., 1993) .
Both unstimulated and stimulated secretion of VEGF were dependent on an active protein biosynthesis because, in the presence of CHX, no release of VEGF was detectable in the cell supernatants. Intracellular staining for VEGF by flow cytometry indicated that the CHX-induced effect was mainly related to an inhibition of the secretion, since VEGF was still detectable at comparable amounts within CHXtreated and untreated cells.
The VEGF identified in the CM of unstimulated HMC-1 cells by Western blotting and ELISA was bioactive, as determined by its capacity to stimulate HM-VEC proliferation in an in vitro assay. With the help of RT-PCR experiments, we could show that these endothelial cells express both types of VEGF receptors (KDR and Flt-1; our unpublished data) and respond to recombinant human VEGF 165 in a dose-dependent manner. Depletion experiments performed with a VEGF-specific mAB resulted in an inhibition of the mitogenic response by up to 90%. The extent of this inhibition was unexpected because unstimulated HMC-1 cells are already known to produce a wide range of angiogenic factors such as histamine, heparin, and TNF-␣ (Meininger and Zetter, 1992) . Obviously, under the culture conditions described, VEGF represents the major endothelial cell mitogenic activity in the CM of unstimulated HMC-1 cells.
The bulk of experiments performed in this study was done with the cell line HMC-1, representing the only established human cell line exhibiting a phenotype similar to that of normal human tissue mast cells (Hamann et al., 1994; Nilsson et al., 1994) . Since VEGF is overexpressed in several transformed cell lines (White et al., 1995) , we cannot exclude the possibility that the expression of VEGF in HMC-1 cells is less a mast cell-associated than a tumor-specific characteristic. But tumor cell lines exhibiting constitutive overexpression of VEGF in general behave in a refractile manner toward phorbol esther activation and do not respond with an additional increase in VEGF abundance (White et al., 1995) , a phenomenon not observed in HMC-1 cells. Furthermore, HMC-1 cells differ from other tumor cell lines in their ability to synthesize all known major VEGF-isoforms. In addition to the neoplastic phenotype of HMC-1 cells, also the grade of maturity of these cells must be taken into account when judging the results presented. HMC-1 cells exhibit a more immature phenotype and, therefore, qualitative and quantitative changes in the expression of VEGF isoforms may occur during mast cell differentiation.
In summary, this study supports the significance of mast cells in angiogenesis. It is evident from the results presented here that mast cells do not only exert an indirectly acting angiogenic response, but that they also may contribute to a direct effect mediated via the expression of VEGF. Finally, the localization of VEGF to a cell that synthesizes heparin in large amounts may help to elucidate the physiological significance of the strongly heparin-binding isoforms VEGF 189 and VEGF 206 .
